Study: Drug given during PCI lowers bleeding risk

10/18/2011 | MedPage Today (free registration)

A trial of more than 8,000 patients led by New York University School of Medicine researchers found bivalirudin administered during PCI saw a decreased bleeding risk compared with the use of heparin or heparin combined with glycoprotein IIb-IIIa inhibitors. Researchers also found no increase in thrombotic or ischemic issues in the 12 months following PCI where bivalirudin was used. The results were published in the journal Circulation: Cardiovascular Interventions.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA